Condition: Colorectal Cancer · Sponsor: Verastem, Inc.
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer
This description comes directly from the study's public registry record.
Verastem Call Center · 7812924204 · VS-7375-203TrialSupport@verastem.com
Luke Chung, MD · VS-7375-203Medical@verastem.com
Always discuss trial participation with your own doctor first.
| START Los Angeles | Los Angeles, California, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| START New Jersey | East Brunswick, New Jersey, United States | Recruiting |
| START Dallas Fort Worth | Fort Worth, Texas, United States | Recruiting |
| START Mountain Region | West Valley City, Utah, United States | Recruiting |
| Icon Cancer Centre South Brisbane | South Brisbane, Queensland, Australia | Recruiting |
| Icon Cancer Centre Adelaide | Kurralta Park, South Australia, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07659795